medwireNews: Study findings published in Rheumatology show that long-term use of colchicine is associated with a decreased risk for adverse renal outcomes in people with hyperuricemia or chronic gout and stage G3–G4 chronic kidney disease (CKD).
The case–control study included data from 3085 individuals with CKD progression, defined as an estimated glomerular filtration rate reduction of at least 40% or the onset of kidney failure with replacement therapy, who were matched to 11,715 controls without CKD progression based on follow-up time, age, and sex.
During a median follow-up of 2.4 years, only 3.2% of individuals with CKD progression were categorized as colchicine users – defined as receipt of at least 90 cumulative daily colchicine doses – compared with 5.0% of those in the control group.
Seung Hyeok Han (Yonsei University, Seoul, South Korea) and fellow investigators report that individuals in the colchicine group had a significant 23% lower risk for CKD progression than nonusers after adjustment for potentially confounding factors. Conversely, receipt of less than 90 cumulative daily colchicine doses and use of other urate-lowering agents were not significantly associated with CKD progression.
Han and colleagues note that the association between colchicine use and reduced CKD progression risk remained consistent when patients were matched according to CKD stage, and was particularly pronounced in people without diabetes or hypertension.
The team concludes: “Our findings warrant well-designed [randomized controlled trials] in the future to test the potential renoprotective effects of colchicine in CKD patients.”
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group